Trial for nutraceutical rich supplement

US company Genetic Services Management, Inc. (GSM) has formulated a dietary supplement that is comprised of 14 different nutraceuticals, each with individually published evidence for potential effectiveness, the company claims. The supplement, called Formula #18, has been designed for (a) those who have had cancer and wish to lower the odds against reoccurrence, and (b) those at an increased risk for cancer. GSM is seeking principal investigators to help implement an international clinical trial to assess the efficacy of its cancer-risk modulating nutraceutical formulation [an open-label Phase II/III trial in which all participants knowingly receive the nutraceutical]. GSM maintains that all of the ingredients are backed by pre-clinical studies, prior observational clinical literature, and/or traditional medical scientific data supporting a cancer risk reduction role. The study is under the overall supervision of Jerome B. Block, M.D., Chief Medical Officer and CEO, GSM and Steven Evans, Senior Research Scientist and President, GSM. To obtain further information about the trial, visit www.cancer-trial.com​